Login Register Cart 0
Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets

Editor-in-Chief

ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Massive Splenomegaly with Pancytopenia in an Adult: Gaucher's Disease

Author(s): Farid Alam, Jitendra Singh*, Nilesh Kumar, Kailash Kumar and Anju Dinkar

Volume 23, Issue 2, 2023

Published on: 24 October, 2023

Page: [136 - 140] Pages: 5

DOI: 10.2174/011871529X253966230922110202

Price: $65

Abstract

Introduction: Gaucher's disease (GD) is a rare lysosomal storage disease. It is characterized by the deposition of glucocerebroside in cells of the macrophage-monocyte system. GD presents a broad clinical expression, including hematologic abnormalities (such as pancytopenia), massive hepatosplenomegaly, diffuse infiltrative pulmonary disease, renal involvement in the form of nephropathy and glomerulonephritis, skeletal involvement in the form of bone pain, bony infarct, osteopenia, and pathological fracture. Based on the presence or absence of neurologic involvement, it is differentiated into type 1, type 2, and type 3. Gaucher’s disease type 1 is the most common form, having the nonneuropathic form and carrying autosomal recessive traits. Gaucher's disease affects all racial and ethnic groups, while type 1 GD is most prevalent among Ashkenazi Jews.

Case Presentation: A 20-year-old female was admitted to the medicine department with complaints of generalized weakness and easy fatigability, menorrhagia, and a dragging sensation in the abdomen. On clinical evaluation, she had bone marrow failure syndrome features along with massive splenomegaly. Later, she was confirmed with Gaucher disease type 1 disease by clinical and investigation (low β-glucosidase level) evaluation.

Conclusion: This case emphasizes keeping a differential diagnosis of glycogen storage disorder while evaluating a case of unexplained pancytopenia with massive splenomegaly in adulthood for an extended period. Currently, enzyme replacement therapy and substrate reduction therapy are the mainstay therapeutic options for GD.

« Previous Next »
Graphical Abstract

[1]
Brady, R.O.; Kanfer, J.N.; Bradley, R.M.; Shapiro, D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher’s disease. J. Clin. Invest., 1966, 45(7), 1112-1115.
[http://dx.doi.org/10.1172/JCI105417] [PMID: 5338605]
[2]
Zimran, A.; Gelbart, T.; Westwood, B.; Grabowski, G.A.; Beutler, E. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am. J. Hum. Genet., 1991, 49(4), 855-859.
[PMID: 1897529]
[3]
Beutler, E.; Grabowski, G.A. Gaucher disease. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed; Scriver, C.; Beaudet, A.L.; Sly, W.S.; Valle, D., Eds.; ; McGraw-Hill: New York, 2001; pp. 3635-3668.
[4]
Riboldi, G.M.; Di Fonzo, A.B. GBA, gaucher disease, and parkinson’s disease: from genetic to clinic to new therapeutic approaches. Cells, 2019, 8(4), 364.
[http://dx.doi.org/10.3390/cells8040364] [PMID: 31010158]
[5]
Kaplan, P.; Andersson, H.C.; Kacena, K.A.; Yee, J.D. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch. Pediatr. Adolesc. Med., 2006, 160(6), 603-608.
[http://dx.doi.org/10.1001/archpedi.160.6.603] [PMID: 16754822]
[6]
Binesh, F.; Yousefi, A.; Ordooei, M.; Bagherinasab, M. Gaucher’s disease, an unusual cause of massive splenomegaly, a case report. Iran. J. Ped. Hematol. Oncol., 2013, 3(4), 173-175.
[PMID: 24575292]
[7]
Bennett, L.L.; Mohan, D. Gaucher disease and its treatment options. Ann. Pharmacother., 2013, 47(9), 1182-1193.
[http://dx.doi.org/10.1177/1060028013500469] [PMID: 24259734]
[8]
Dandana, A.; Ben Khelifa, S.; Chahed, H.; Miled, A.; Ferchichi, S. Gaucher disease: Clinical, biological and therapeutic aspects. Pathobiology, 2016, 83(1), 13-23.
[http://dx.doi.org/10.1159/000440865] [PMID: 26588331]
[9]
Levrat, V.; Forest, I.; Fouilhoux, A.; Guffon, N. Maladie de Gaucher: particularités cliniques chez l’enfant. Rev. Med. Interne, 2007, 28(Suppl. 2), 183-186.
[http://dx.doi.org/10.1016/S0248-8663(07)78879-3] [PMID: 18228686]
[10]
Singh, J.; Dinkar, A.; Gupta, P.; Atam, V. Vitamin B12 deficiency in northern India tertiary care: Prevalence, risk factors and clinical characteristics. J. Family Med. Prim. Care, 2022, 11(6), 2381-2388.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_650_21] [PMID: 36119310]
[11]
Dinkar, A.; Singh, J. Dengue infection in North India: An experience of a tertiary care center from 2012 to 2017. Tzu-Chi Med. J., 2019, 32(1), 36-40.
[PMID: 32110518]
[12]
Singh, J.; Dinkar, A.; Kumar, N.; Kumar, K. COVID-19 Associated Pancytopenia (CAP): A clinical impact. Recent Adv Inflamm Allergy Drug Discov, 2023, 17(1), 71-78.
[http://dx.doi.org/10.2174/2772270817666221207094122]
[13]
Maas, M.; Poll, L.W.; Terk, M.R. Imaging and quantifying skeletal involvement in Gaucher disease. Br. J. Radiol., 2002, 75(Suppl. 1), A13-A24.
[http://dx.doi.org/10.1259/bjr.75.suppl_1.750013] [PMID: 12036829]
[14]
Kuter, D.J.; Mehta, A.; Hollak, C.E.M.; Giraldo, P.; Hughes, D.; Belmatoug, N.; Brand, M.; Muller, A.; Schaaf, B.; Giorgino, R.; Zimran, A. Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol. Dis., 2013, 51(2), 116-124.
[http://dx.doi.org/10.1016/j.bcmd.2013.04.005] [PMID: 23683771]
[15]
Sechi, A.; Dardis, A.; Bembi, B. Profile of eliglustat tartrate in the management of Gaucher disease. Ther. Clin. Risk Manag., 2016, 12, 53-58.
[http://dx.doi.org/10.2147/TCRM.S73226] [PMID: 26811686]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy